Launch brings Novodiag’s benefits to broader range of European customers and expands Hologic’s offering of world-leading molecular scalable solutions
Manchester, UK, October 5, 2021 – Hologic, Inc. (Nasdaq: HOLX) today announced its broad European launch of the Novodiag® system, a fully automated molecular diagnostic solution for on-demand testing of infectious diseases and antimicrobial resistance. The launch follows Hologic’s acquisition of Mobidiag Oy in June 2021 and will bring the benefits of the Novodiag system to a broader range of customers in Europe.